Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease. / Dencker, Ditte; Thomsen, Morgane; Wörtwein, Gitta; Weikop, Pia; Cui, Yinghong; Jeon, Jongrye; Wess, Jürgen; Fink-Jensen, Anders.

In: ACS Chemical Neuroscience, Vol. 3, No. 2, 22.11.2011, p. 80-89.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Dencker, D, Thomsen, M, Wörtwein, G, Weikop, P, Cui, Y, Jeon, J, Wess, J & Fink-Jensen, A 2011, 'Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease', ACS Chemical Neuroscience, vol. 3, no. 2, pp. 80-89. https://doi.org/10.1021/cn200110q

APA

Dencker, D., Thomsen, M., Wörtwein, G., Weikop, P., Cui, Y., Jeon, J., Wess, J., & Fink-Jensen, A. (2011). Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease. ACS Chemical Neuroscience, 3(2), 80-89. https://doi.org/10.1021/cn200110q

Vancouver

Dencker D, Thomsen M, Wörtwein G, Weikop P, Cui Y, Jeon J et al. Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease. ACS Chemical Neuroscience. 2011 Nov 22;3(2):80-89. https://doi.org/10.1021/cn200110q

Author

Dencker, Ditte ; Thomsen, Morgane ; Wörtwein, Gitta ; Weikop, Pia ; Cui, Yinghong ; Jeon, Jongrye ; Wess, Jürgen ; Fink-Jensen, Anders. / Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease. In: ACS Chemical Neuroscience. 2011 ; Vol. 3, No. 2. pp. 80-89.

Bibtex

@article{000f3c61a6854f789e30d51a8f3f0029,
title = "Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease",
abstract = "The neurotransmitter dopamine plays important roles in modulating cognitive, affective, and motor functions. Dysregulation of dopaminergic neurotransmission is thought to be involved in the pathophysiology of several psychiatric and neurological disorders, including schizophrenia, Parkinson's disease and drug abuse. Dopaminergic systems are regulated by cholinergic, especially muscarinic, input. Not surprisingly, increasing evidence implicates muscarinic acetylcholine receptor-mediated pathways as potential targets for the treatment of these disorders classically viewed as {"}dopamine based{"}. There are five known muscarinic receptor subtypes (M(1) to M(5)). Due to their overlapping expression patterns and the lack of receptor subtype-specific ligands, the roles of the individual muscarinic receptors have long remained elusive. During the past decade, studies with knock-out mice lacking specific muscarinic receptor subtypes have greatly advanced our knowledge of the physiological roles of the M(1)-M(5) receptors. Recently, new ligands have been developed that can interact with allosteric sites on different muscarinic receptor subtypes, rather than the conventional (orthosteric) acetylcholine binding site. Such agents may lead to the development of novel classes of drugs useful for the treatment of psychosis, drug abuse and Parkinson's disease. The present review highlights recent studies carried out using muscarinic receptor knock-out mice and new subtype-selective allosteric ligands to assess the roles of M(1), M(4), and M(5) receptors in various central processes that are under strong dopaminergic control. The outcome of these studies opens new perspectives for the use of novel muscarinic drugs for several severe disorders of the CNS.",
author = "Ditte Dencker and Morgane Thomsen and Gitta W{\"o}rtwein and Pia Weikop and Yinghong Cui and Jongrye Jeon and J{\"u}rgen Wess and Anders Fink-Jensen",
year = "2011",
month = nov,
day = "22",
doi = "10.1021/cn200110q",
language = "English",
volume = "3",
pages = "80--89",
journal = "A C S Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "2",

}

RIS

TY - JOUR

T1 - Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease

AU - Dencker, Ditte

AU - Thomsen, Morgane

AU - Wörtwein, Gitta

AU - Weikop, Pia

AU - Cui, Yinghong

AU - Jeon, Jongrye

AU - Wess, Jürgen

AU - Fink-Jensen, Anders

PY - 2011/11/22

Y1 - 2011/11/22

N2 - The neurotransmitter dopamine plays important roles in modulating cognitive, affective, and motor functions. Dysregulation of dopaminergic neurotransmission is thought to be involved in the pathophysiology of several psychiatric and neurological disorders, including schizophrenia, Parkinson's disease and drug abuse. Dopaminergic systems are regulated by cholinergic, especially muscarinic, input. Not surprisingly, increasing evidence implicates muscarinic acetylcholine receptor-mediated pathways as potential targets for the treatment of these disorders classically viewed as "dopamine based". There are five known muscarinic receptor subtypes (M(1) to M(5)). Due to their overlapping expression patterns and the lack of receptor subtype-specific ligands, the roles of the individual muscarinic receptors have long remained elusive. During the past decade, studies with knock-out mice lacking specific muscarinic receptor subtypes have greatly advanced our knowledge of the physiological roles of the M(1)-M(5) receptors. Recently, new ligands have been developed that can interact with allosteric sites on different muscarinic receptor subtypes, rather than the conventional (orthosteric) acetylcholine binding site. Such agents may lead to the development of novel classes of drugs useful for the treatment of psychosis, drug abuse and Parkinson's disease. The present review highlights recent studies carried out using muscarinic receptor knock-out mice and new subtype-selective allosteric ligands to assess the roles of M(1), M(4), and M(5) receptors in various central processes that are under strong dopaminergic control. The outcome of these studies opens new perspectives for the use of novel muscarinic drugs for several severe disorders of the CNS.

AB - The neurotransmitter dopamine plays important roles in modulating cognitive, affective, and motor functions. Dysregulation of dopaminergic neurotransmission is thought to be involved in the pathophysiology of several psychiatric and neurological disorders, including schizophrenia, Parkinson's disease and drug abuse. Dopaminergic systems are regulated by cholinergic, especially muscarinic, input. Not surprisingly, increasing evidence implicates muscarinic acetylcholine receptor-mediated pathways as potential targets for the treatment of these disorders classically viewed as "dopamine based". There are five known muscarinic receptor subtypes (M(1) to M(5)). Due to their overlapping expression patterns and the lack of receptor subtype-specific ligands, the roles of the individual muscarinic receptors have long remained elusive. During the past decade, studies with knock-out mice lacking specific muscarinic receptor subtypes have greatly advanced our knowledge of the physiological roles of the M(1)-M(5) receptors. Recently, new ligands have been developed that can interact with allosteric sites on different muscarinic receptor subtypes, rather than the conventional (orthosteric) acetylcholine binding site. Such agents may lead to the development of novel classes of drugs useful for the treatment of psychosis, drug abuse and Parkinson's disease. The present review highlights recent studies carried out using muscarinic receptor knock-out mice and new subtype-selective allosteric ligands to assess the roles of M(1), M(4), and M(5) receptors in various central processes that are under strong dopaminergic control. The outcome of these studies opens new perspectives for the use of novel muscarinic drugs for several severe disorders of the CNS.

U2 - 10.1021/cn200110q

DO - 10.1021/cn200110q

M3 - Journal article

C2 - 22389751

VL - 3

SP - 80

EP - 89

JO - A C S Chemical Neuroscience

JF - A C S Chemical Neuroscience

SN - 1948-7193

IS - 2

ER -

ID: 41851748